董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Cohen | 男 | Independent Director | 67 | 5.77万美元 | 6.06 | 2026-03-01 |
| Ilan Danieli | 男 | Chief Executive Officer and Director | 54 | 47.27万美元 | 5.19 | 2026-03-01 |
| Jeffrey Cossman | 男 | Independent Director | 78 | 4.72万美元 | 2.37 | 2026-03-01 |
| Kathleen LaPorte | -- | Independent Director | -- | 5.52万美元 | 2.08 | 2026-03-01 |
| Richard Sandberg | -- | Chairman of the Board and Director | -- | 8.02万美元 | 3.33 | 2026-03-01 |
| Christina Valauri | -- | Independent Director | -- | 4.42万美元 | 0.76 | 2026-03-01 |
| Ronald Andrews | -- | Independent Director | -- | 4.52万美元 | 未持股 | 2026-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ilan Danieli | 男 | Chief Executive Officer and Director | 54 | 47.27万美元 | 5.19 | 2026-03-01 |
| Ahmed Zaki Sabet | 男 | Chief Operating Officer | 40 | 30.87万美元 | 2.20 | 2026-03-01 |
| Ayman Mohamed | 男 | Chief Technology Officer | 41 | 31.21万美元 | 2.33 | 2026-03-01 |
| Matthew Gage | 男 | Chief Financial Officer | 59 | 未披露 | 未持股 | 2026-03-01 |
董事简历
中英对照 | 中文 | 英文- David Cohen
-
David Cohen先生。Cohen是康涅狄格州最大的独立石油零售公司Standard Oil of Connecticut, Inc.的首席运营官和共同所有人。他创立了几家非常成功的企业，包括：Standard Security Systems（电子安全服务提供商）；ResCom能源公司，一家多州电力供应商；Moneo Technology Solutions，安全和网络基础设施解决方案提供商；以及癌症生物信息公司My Gene Counsel。他目前任职于eBrevia、Emme Controls、Foresite MSP、My Gene Counsel、the Platt & LaBonia Company和Sirona Medical Technologies的董事会。他持有Harvard College的学士学位和the Harvard Business School的工商管理硕士学位。Cohen先生自2017年11月起被任命为公司董事。
David Cohen,Mr. Cohen is the Chief Operating Officer and co-owner of Standard Oil of Connecticut, Inc., the largest independent petroleum retailing company in Connecticut. He founded several highly successful ventures, including: Standard Security Systems, a provider of electronic security services; ResCom Energy, a multi-state supplier of deregulated electricity; Moneo Technology Solutions, a provider of security and network infrastructure solutions; and My Gene Counsel, a cancer bioinformatics company. He currently serves on the Boards of: eBrevia, Emme Controls, Foresite MSP, My Gene Counsel, The Platt & LaBonia Company, and Sirona Medical Technologies. Mr. Cohen holds a B.A. from Harvard College and an MBA from the Harvard Business School. Mr. Cohen was appointed as director of the Company since November 2017. - David Cohen先生。Cohen是康涅狄格州最大的独立石油零售公司Standard Oil of Connecticut, Inc.的首席运营官和共同所有人。他创立了几家非常成功的企业，包括：Standard Security Systems（电子安全服务提供商）；ResCom能源公司，一家多州电力供应商；Moneo Technology Solutions，安全和网络基础设施解决方案提供商；以及癌症生物信息公司My Gene Counsel。他目前任职于eBrevia、Emme Controls、Foresite MSP、My Gene Counsel、the Platt & LaBonia Company和Sirona Medical Technologies的董事会。他持有Harvard College的学士学位和the Harvard Business School的工商管理硕士学位。Cohen先生自2017年11月起被任命为公司董事。
- David Cohen,Mr. Cohen is the Chief Operating Officer and co-owner of Standard Oil of Connecticut, Inc., the largest independent petroleum retailing company in Connecticut. He founded several highly successful ventures, including: Standard Security Systems, a provider of electronic security services; ResCom Energy, a multi-state supplier of deregulated electricity; Moneo Technology Solutions, a provider of security and network infrastructure solutions; and My Gene Counsel, a cancer bioinformatics company. He currently serves on the Boards of: eBrevia, Emme Controls, Foresite MSP, My Gene Counsel, The Platt & LaBonia Company, and Sirona Medical Technologies. Mr. Cohen holds a B.A. from Harvard College and an MBA from the Harvard Business School. Mr. Cohen was appointed as director of the Company since November 2017.
- Ilan Danieli
-
Ilan Danieli是Precipio Diagnostics LLC的创始人，自2011年起担任Precipio Diagnostics LLC的首席执行官。Danieli先生在合并时担任Precipio，Inc.的首席执行官，其定义如下。他曾担任Osiris公司（上市公司，位于纽约市，业务遍及美国、加拿大、欧洲和亚洲）的首席运营官，也曾担任Laurus Capital Management公司的运营副总裁。数十亿美元的对冲基金；以及其他各种创业投资。Ilan持有the University of Virginia Darden School工商管理硕士学位，以及以色列Bar-Ilan University经济学学士学位。
Ilan Danieli was the founder of Precipio Diagnostics LLC and was the Chief Executive Officer of Precipio Diagnostics LLC since 2011. Mr. Danieli assumed the role of Chief Executive Officer of Precipio, Inc. at the time of a June 2017 merger transaction with Transgenomic, Inc. (the "Merger"). With over 20 years managing small and medium size companies, some of his previous experiences include serving as COO of Osiris, a publicly traded company based in New York City with operations in the US, Canada, Europe and Asia, VP of Operations for Laurus Capital Management, a multi billion dollar hedge fund, and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar Ilan University in Israel. - Ilan Danieli是Precipio Diagnostics LLC的创始人，自2011年起担任Precipio Diagnostics LLC的首席执行官。Danieli先生在合并时担任Precipio，Inc.的首席执行官，其定义如下。他曾担任Osiris公司（上市公司，位于纽约市，业务遍及美国、加拿大、欧洲和亚洲）的首席运营官，也曾担任Laurus Capital Management公司的运营副总裁。数十亿美元的对冲基金；以及其他各种创业投资。Ilan持有the University of Virginia Darden School工商管理硕士学位，以及以色列Bar-Ilan University经济学学士学位。
- Ilan Danieli was the founder of Precipio Diagnostics LLC and was the Chief Executive Officer of Precipio Diagnostics LLC since 2011. Mr. Danieli assumed the role of Chief Executive Officer of Precipio, Inc. at the time of a June 2017 merger transaction with Transgenomic, Inc. (the "Merger"). With over 20 years managing small and medium size companies, some of his previous experiences include serving as COO of Osiris, a publicly traded company based in New York City with operations in the US, Canada, Europe and Asia, VP of Operations for Laurus Capital Management, a multi billion dollar hedge fund, and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar Ilan University in Israel.
- Jeffrey Cossman
-
Jeffrey Cossman，科斯曼博士于2009年至2014年担任United States Diagnostic Standards，Inc.的创始人兼首席执行官兼董事会主席，并于2008年至2014年担任个性化医疗联盟的董事会成员。此前，他曾担任The Critical Path Institute的首席科学官和董事会成员，以及Gene Logic，Inc.的医学董事。他曾担任Georgetown University Medical Center的教授兼病理学系主席，在那里他曾担任Oscar Benwood Hunter病理学主席，也曾担任the National Cancer Institute的血液病理学高级研究员。他目前是EpiGenomics AG的医学顾问。Cossman博士拥有密歇根大学（University of Michigan）的B.S.和密歇根大学（University of Michigan）医学院的医学博士学位。他在密歇根大学（University of Michigan）、斯坦福大学（Stanford University）和美国国立卫生研究院（National Institutes of Health）获得病理学委员会认证，并接受病理学和血液病理学培训。Cossman博士自2017年9月起被任命为公司董事。
Jeffrey Cossman,Dr. Cossman was a founder of and served as Chief Executive Officer and Chairman of the Board at United States Diagnostic Standards, Inc. from 2009 to 2014 and as a member of the Board of The Personalized Medicine Coalition from 2008 to 2014. Prior to that, he served as Chief Scientific Officer and as member of the Board of Directors of The Critical Path Institute, and as Medical Director of Gene Logic, Inc. He was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center where he held the Oscar Benwood Hunter Chair of Pathology and he served as Senior Investigator in Hematopathology at the National Cancer Institute. He is currently a medical advisor to Epigenomics AG. Dr. Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is board-certified in pathology and trained in pathology and hematopathology at the University of Michigan, Stanford University and the National Institutes of Health. Dr. Cossman was appointed as director of the Company since September 2017. - Jeffrey Cossman，科斯曼博士于2009年至2014年担任United States Diagnostic Standards，Inc.的创始人兼首席执行官兼董事会主席，并于2008年至2014年担任个性化医疗联盟的董事会成员。此前，他曾担任The Critical Path Institute的首席科学官和董事会成员，以及Gene Logic，Inc.的医学董事。他曾担任Georgetown University Medical Center的教授兼病理学系主席，在那里他曾担任Oscar Benwood Hunter病理学主席，也曾担任the National Cancer Institute的血液病理学高级研究员。他目前是EpiGenomics AG的医学顾问。Cossman博士拥有密歇根大学（University of Michigan）的B.S.和密歇根大学（University of Michigan）医学院的医学博士学位。他在密歇根大学（University of Michigan）、斯坦福大学（Stanford University）和美国国立卫生研究院（National Institutes of Health）获得病理学委员会认证，并接受病理学和血液病理学培训。Cossman博士自2017年9月起被任命为公司董事。
- Jeffrey Cossman,Dr. Cossman was a founder of and served as Chief Executive Officer and Chairman of the Board at United States Diagnostic Standards, Inc. from 2009 to 2014 and as a member of the Board of The Personalized Medicine Coalition from 2008 to 2014. Prior to that, he served as Chief Scientific Officer and as member of the Board of Directors of The Critical Path Institute, and as Medical Director of Gene Logic, Inc. He was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center where he held the Oscar Benwood Hunter Chair of Pathology and he served as Senior Investigator in Hematopathology at the National Cancer Institute. He is currently a medical advisor to Epigenomics AG. Dr. Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is board-certified in pathology and trained in pathology and hematopathology at the University of Michigan, Stanford University and the National Institutes of Health. Dr. Cossman was appointed as director of the Company since September 2017.
- Kathleen LaPorte
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Richard Sandberg
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Christina Valauri
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Ronald Andrews
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Ilan Danieli
Ilan Danieli是Precipio Diagnostics LLC的创始人，自2011年起担任Precipio Diagnostics LLC的首席执行官。Danieli先生在合并时担任Precipio，Inc.的首席执行官，其定义如下。他曾担任Osiris公司（上市公司，位于纽约市，业务遍及美国、加拿大、欧洲和亚洲）的首席运营官，也曾担任Laurus Capital Management公司的运营副总裁。数十亿美元的对冲基金；以及其他各种创业投资。Ilan持有the University of Virginia Darden School工商管理硕士学位，以及以色列Bar-Ilan University经济学学士学位。
Ilan Danieli was the founder of Precipio Diagnostics LLC and was the Chief Executive Officer of Precipio Diagnostics LLC since 2011. Mr. Danieli assumed the role of Chief Executive Officer of Precipio, Inc. at the time of a June 2017 merger transaction with Transenomic, Inc. (the "Merger"). With over 20 years managing small and medium size companies, some of his previous experiences include serving as COO of Osiris, a publicly traded company based in New York City with operations in the US, Canada, Europe and Asia, VP of Operations for Laurus Capital Management, a multi billion dollar hedge fund, and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar Ilan University in Israel.- Ilan Danieli是Precipio Diagnostics LLC的创始人，自2011年起担任Precipio Diagnostics LLC的首席执行官。Danieli先生在合并时担任Precipio，Inc.的首席执行官，其定义如下。他曾担任Osiris公司（上市公司，位于纽约市，业务遍及美国、加拿大、欧洲和亚洲）的首席运营官，也曾担任Laurus Capital Management公司的运营副总裁。数十亿美元的对冲基金；以及其他各种创业投资。Ilan持有the University of Virginia Darden School工商管理硕士学位，以及以色列Bar-Ilan University经济学学士学位。
- Ilan Danieli was the founder of Precipio Diagnostics LLC and was the Chief Executive Officer of Precipio Diagnostics LLC since 2011. Mr. Danieli assumed the role of Chief Executive Officer of Precipio, Inc. at the time of a June 2017 merger transaction with Transenomic, Inc. (the "Merger"). With over 20 years managing small and medium size companies, some of his previous experiences include serving as COO of Osiris, a publicly traded company based in New York City with operations in the US, Canada, Europe and Asia, VP of Operations for Laurus Capital Management, a multi billion dollar hedge fund, and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar Ilan University in Israel.
- Ahmed Zaki Sabet
Ahmed Zaki Sabet自2011年共同创立公司以来一直任职于Precipio，目前担任首席运营官。Sabet先生在实验室管理方面拥有超过17年的经验，涵盖主要专注于癌症诊断的参考实验室运营的所有领域。在加入Precipio之前，Sabet先生曾担任美国病理学家学院（CAP）的顾问，并协助多家诊断公司建立其专门的癌症检测业务。Sabet先生拥有新泽西理工学院生物医学工程理学学士学位。
Ahmed Zaki Sabet has been with Precipio since co founding the Company in 2011 and currently serves as the Chief Operating Officer. Mr. Sabet holds over 17 years of experience in laboratory management spanning all fields of reference laboratory operations primarily focusing on cancer diagnostics. Prior to Precipio, Mr. Sabet has served as a consultant with the College of American Pathologists (CAP) and assisted several diagnostic companies in setting up their specialized cancer testing operations. Mr. Sabet holds a Bachelor of Science degree in Biomedical Engineering from the New Jersey Institute of Technology.- Ahmed Zaki Sabet自2011年共同创立公司以来一直任职于Precipio，目前担任首席运营官。Sabet先生在实验室管理方面拥有超过17年的经验，涵盖主要专注于癌症诊断的参考实验室运营的所有领域。在加入Precipio之前，Sabet先生曾担任美国病理学家学院（CAP）的顾问，并协助多家诊断公司建立其专门的癌症检测业务。Sabet先生拥有新泽西理工学院生物医学工程理学学士学位。
- Ahmed Zaki Sabet has been with Precipio since co founding the Company in 2011 and currently serves as the Chief Operating Officer. Mr. Sabet holds over 17 years of experience in laboratory management spanning all fields of reference laboratory operations primarily focusing on cancer diagnostics. Prior to Precipio, Mr. Sabet has served as a consultant with the College of American Pathologists (CAP) and assisted several diagnostic companies in setting up their specialized cancer testing operations. Mr. Sabet holds a Bachelor of Science degree in Biomedical Engineering from the New Jersey Institute of Technology.
- Ayman Mohamed
Ayman Mohamed自2011年共同创立公司以来一直任职于Precipio，目前担任首席技术官，同时也是实验室的技术总监。在这一双重角色中，穆罕默德博士负责从专有技术的概念化和发明，到设计和开发、经济成本分析和建模、测试和验证的整个过程；最后，技术在公司实验室的临床应用的技术实施。Dr. Mohamed一直负责IV Cell等突破性产品的研发和导入和HemeScreen。在加入公司之前，Mohamed博士曾在商业诊断公司以及耶鲁大学等学术中心担任过各种技术和研究职务。Mohamed博士拥有埃及亚历山大大学的医学博士和人类遗传学硕士学位。
Ayman Mohamed has been with Precipio since co founding the Company in 2011, and currently serves as the Chief Technology Officer, as well as the laboratory's Technical Director. In this dual role, Dr. Mohamed is responsible for the entire process from conceptualization and invention of proprietary technologies, through design and development, economic cost analysis and modeling, testing and validation; and finally, the technical implementation of the technologies for clinical use in the Company's laboratories. Dr. Mohamed has been responsible for the development and introduction of ground breaking products such as IV Cell and HemeScreen. Prior to joining the Company, Dr. Mohamed served in various technical and research positions in both commercial diagnostic companies as well as academic centers such as Yale University. Dr. Mohamed holds an MD and a Masters in Human Genetics from the University of Alexandria, Egypt.- Ayman Mohamed自2011年共同创立公司以来一直任职于Precipio，目前担任首席技术官，同时也是实验室的技术总监。在这一双重角色中，穆罕默德博士负责从专有技术的概念化和发明，到设计和开发、经济成本分析和建模、测试和验证的整个过程；最后，技术在公司实验室的临床应用的技术实施。Dr. Mohamed一直负责IV Cell等突破性产品的研发和导入和HemeScreen。在加入公司之前，Mohamed博士曾在商业诊断公司以及耶鲁大学等学术中心担任过各种技术和研究职务。Mohamed博士拥有埃及亚历山大大学的医学博士和人类遗传学硕士学位。
- Ayman Mohamed has been with Precipio since co founding the Company in 2011, and currently serves as the Chief Technology Officer, as well as the laboratory's Technical Director. In this dual role, Dr. Mohamed is responsible for the entire process from conceptualization and invention of proprietary technologies, through design and development, economic cost analysis and modeling, testing and validation; and finally, the technical implementation of the technologies for clinical use in the Company's laboratories. Dr. Mohamed has been responsible for the development and introduction of ground breaking products such as IV Cell and HemeScreen. Prior to joining the Company, Dr. Mohamed served in various technical and research positions in both commercial diagnostic companies as well as academic centers such as Yale University. Dr. Mohamed holds an MD and a Masters in Human Genetics from the University of Alexandria, Egypt.
- Matthew Gage
Matthew Gage此前曾担任Precipio, Inc.的财务报告和分析总监，该公司于2017年6月收购Transgenomic Inc.后加入该公司，自2014年起担任该公司的财务报告和分析总监。Gage先生在企业融资方面拥有30多年的经验，其中25年曾在上市公司任职。Gage先生拥有布莱恩特大学工商管理理学学士学位。
Matthew Gage previously served as Director of Financial Reporting and Analysis of Precipio, Inc., upon joining the Company in June 2017 following its acquisition of Transgenomic Inc., where he was Director of Financial Reporting and Analysis since 2014. Mr. Gage has over 30 years of experience in corporate finance, 25 years of which being with publicly traded companies. Mr. Gage holds a Bachelor of Science Degree in Business Administration from Bryant University.- Matthew Gage此前曾担任Precipio, Inc.的财务报告和分析总监，该公司于2017年6月收购Transgenomic Inc.后加入该公司，自2014年起担任该公司的财务报告和分析总监。Gage先生在企业融资方面拥有30多年的经验，其中25年曾在上市公司任职。Gage先生拥有布莱恩特大学工商管理理学学士学位。
- Matthew Gage previously served as Director of Financial Reporting and Analysis of Precipio, Inc., upon joining the Company in June 2017 following its acquisition of Transgenomic Inc., where he was Director of Financial Reporting and Analysis since 2014. Mr. Gage has over 30 years of experience in corporate finance, 25 years of which being with publicly traded companies. Mr. Gage holds a Bachelor of Science Degree in Business Administration from Bryant University.